Esomeprazole Jubilant Magasýruþolin tafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

esomeprazole jubilant magasýruþolin tafla 20 mg

jubilant pharmaceuticals nv - esomeprazolum magnesíum - magasýruþolin tafla - 20 mg

Esomeprazole Jubilant Magasýruþolin tafla 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

esomeprazole jubilant magasýruþolin tafla 40 mg

jubilant pharmaceuticals nv - esomeprazolum magnesíum - magasýruþolin tafla - 40 mg

Nexium Magasýruþolin tafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

nexium magasýruþolin tafla 20 mg

grünenthal gmbh* - esomeprazolum magnesíum - magasýruþolin tafla - 20 mg

Nexium Magasýruþolin tafla 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

nexium magasýruþolin tafla 40 mg

grünenthal gmbh* - esomeprazolum magnesíum - magasýruþolin tafla - 40 mg

Nexium Mixtúrukyrni, dreifa 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

nexium mixtúrukyrni, dreifa 10 mg

grünenthal gmbh* - esomeprazolum magnesíum - mixtúrukyrni, dreifa - 10 mg

Nexium Stungulyfs-/innrennslisstofn, lausn 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

nexium stungulyfs-/innrennslisstofn, lausn 40 mg

grünenthal gmbh* - esomeprazolum natríum - stungulyfs-/innrennslisstofn, lausn - 40 mg

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Evrópusambandið - íslenska - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - blóðþurrðandi lyf - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Nexium Control Evrópusambandið - íslenska - EMA (European Medicines Agency)

nexium control

glaxosmithkline dungarvan limited - esomeprazol - meltingarfærakvilla - róteind dæla hemlar - nexium control er ætlað til skamms tíma meðhöndlunar á bakflæðissjúkdómum (e. brjóstsviða og sýruuppfall) hjá fullorðnum.

Esomeprazol Krka Magasýruþolið hart hylki 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

esomeprazol krka magasýruþolið hart hylki 20 mg

krka sverige ab - esomeprazolum magnesíum díhýdrat - magasýruþolið hart hylki - 20 mg

Esomeprazol Krka Magasýruþolið hart hylki 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

esomeprazol krka magasýruþolið hart hylki 40 mg

krka sverige ab - esomeprazolum magnesíum díhýdrat - magasýruþolið hart hylki - 40 mg